BioCryst Presents New Real-world Data Showing Rapid, Substantial and Sustained HAE Attack Rate Reductions After Beginning ORLADEYO (berotralstat) Treatment
23.02.2024 - RESEARCH TRIANGLE PARK, N.C., Feb. 23, 2024 (GLOBE NEWSWIRE) - BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced new analyses of real-world use of oral, once-daily ORLADEYO (berotralstat) that showed patients who initiated ORLADEYO ... Seite 1
United States Bryan Arnold Jonathan Bernstein Bernstein Clinical Research Center University Of Cincinnati Bernstein Allergy Group
Source: wallstreet-online.de